文献速递肝病

α1-抗胰蛋白酶调控小鼠和人类酒精相关性肝病

Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans.
PubMed 文献 · Gut · 2020-07-22

研究纳入512例肝硬化患者,发现血清α1-抗胰蛋白酶(AAT)浓度低于120 mg/dL的酒精相关性肝病(ALD)肝硬化患者死亡/肝移植风险显著高于高于120 mg/dL者。动物实验显示乙醇喂养野生型小鼠肝脏AAT下降,而hAAT-Tg小鼠及接受人AAT治疗的野生型小鼠均表现出对乙醇诱导肝损伤的保护作用。

要点

  • 肝硬化ALD患者AAT血清浓度<120 mg/dL者死亡/肝移植风险显著高于>120 mg/dL者。
  • 低AAT血清浓度是生存/移植的NaMELD独立预测因素。
  • hAAT-Tg小鼠和AAT治疗的野生型小鼠均免受乙醇诱导的肝损伤。

核心结论

  • 肝硬化ALD患者AAT浓度<120 mg/dL者死亡/肝移植风险增加。
  • hAAT-Tg小鼠和AAT治疗的野生型动物均表现出对乙醇诱导肝损伤的保护作用。
  • AAT可能成为人类ALD的治疗选择,尤其是酒精性肝炎。

研究设计与样本

  • 研究纳入512例肝硬化患者进行临床特征分析,比较ALD与其他病因肝病患者的生存、临床和生化参数包括AAT血清浓度。
  • 在实验性ALD模型中评估AAT的作用。

主要发现

  • AAT血清浓度<120 mg/dL的肝硬化ALD患者死亡/肝移植风险显著高于AAT血清浓度>120 mg/dL者。
  • 多因素Cox回归分析显示低AAT血清浓度是生存/移植的NaMELD独立预测因素。
  • 乙醇喂养野生型小鼠较配对喂养小鼠肝脏AAT显著下降。
  • hAAT-Tg小鼠乙醇喂养后表现出肝损伤保护,伴有脂肪变性减少、肝中性粒细胞浸润减少和促炎细胞因子表达减弱。
  • 乙醇喂养野生型小鼠接受人AAT治疗后,肝损伤、中性粒细胞浸润和脂肪变性均改善。

关键数值与推荐

  • 肝硬化ALD患者AAT血清浓度<120 mg/dL者死亡/肝移植风险显著高于>120 mg/dL者。
  • 低AAT血清浓度是生存/移植的NaMELD独立预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Alcohol-related liver disease (ALD) is a global healthcare problem with limited treatment options. Alpha-1 antitrypsin (AAT, encoded by SERPINA1) shows potent anti-inflammatory activities in many preclinical and clinical trials. In our study, we aimed to explore the role of AAT in ALD. DESIGN: An unselected cohort of 512 patients with cirrhosis was clinically characterised. Survival, clinical and biochemical parameters including AAT serum concentration were compared between patients with ALD and other aetiologies of liver disease. The role of AAT was evaluated in experimental ALD models. RESULTS: Cirrhotic ALD patients with AAT serum concentrations less than 120 mg/dL had a significantly higher risk for death/liver transplantation as compared with patients with AAT serum concentrations higher than 120 mg/dL. Multivariate Cox regression analysis showed that low AAT serum concentration was a NaMELD-independent predictor of survival/transplantation. Ethanol-fed wild-type (wt) mice displayed a significant decline in hepatic AAT compared with pair-fed mice. Therefore, hAAT-Tg mice were ethanol-fed, and these mice displayed protection from liver injury associated with decreased steatosis, hepatic neutrophil infiltration and abated expression of proinflammatory cytokines. To test the therapeutic capability of AAT, ethanol-fed wt mice were treated with human AAT. Administration of AAT ameliorated hepatic injury, neutrophil infiltration and steatosis. CONCLUSION: Cirrhotic ALD patients with AAT concentrations less than 120 mg/dL displayed an increased risk for death/liver transplantation. Both hAAT-Tg mice and AAT-treated wt animals showed protection from ethanol-induced liver injury. AAT could reflect a treatment option for human ALD, especially for alcoholic hepatitis.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Grander C, Schaefer B, Schwärzler J, et al. Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. Gut. 2020. PMID: 32699098. doi:10.1136/gutjnl-2020-321375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。